Inhibitors of tyrosine kinase receptor dimerization
AssigneeWashington University
InventorsGarland R. Marshall, Linda J. Pike, Robert Yang
Life of this patent
Estimating the term…
Loading patent…
AssigneeWashington University
InventorsGarland R. Marshall, Linda J. Pike, Robert Yang
Estimating the term…
The teachings relate to methods of identifying inhibitors of dimerization of tyrosine receptor kinases such as EGFR. The methods comprise providing, on a digital computer, a molecular model comprising a complex of extracellular dimerization domains of an RTK, docking a chemical databases to the molecular model, scoring the compounds comprised by the database, and identifying one or more high-scoring compounds. The methods further comprise testing a compound for RTK inhibitory activity in vitro, and testing a compound for specificity as an RTK inhibitor. Also disclosed are compounds selected by the described methods, and methods of treatment using the compounds. Two compounds (NSC11241 and NSC56452) are disclosed that inhibit EGF receptor kinase activation in a dose-dependent manner.
A method of identifying one or more inhibitors of heterodimerization or homodimerization of activated extracellular domains of at least one tyrosine receptor kinase (RTK), the method comprising:
A novel compound or a salt thereof, selected from the group consisting of an analog of Compound NSC11241 or a salt thereof, an analog of Compound NSC309895 or a salt thereof, an analog of Compound NSC303769 or a salt thereof, and an analog of Compound NSC56452 or a salt thereof, Compound NSC11241 or a salt thereof, Compound NSC309895 or a salt thereof, Compound NSC303769 or a salt thereof, and Compound NSC56452 or a salt thereof, wherein the compound or salt thereof is an inhibitor of RTK dimerization.
Dependencies are inferred from the claim text.